Curated News
By: NewsRamp Editorial Staff
May 05, 2025
NRx Pharmaceuticals Files Patent for NRX-100 IV Ketamine Formulation for Suicidal Depression
TLDR
- NRx Pharmaceuticals filed a patent application for NRX-100, targeting suicidal depression, potentially securing exclusivity through 2045.
- NRX-100, a preservative-free intravenous ketamine formulation, could qualify for FDA Orange Book listing due to its stability and lack of toxic preservatives.
- NRx Pharmaceuticals' NRX-100 aims to provide a safer and more effective treatment for suicidal depression, potentially improving mental health outcomes and reducing mortality rates.
- NRX-100's innovative design without toxic preservatives and room temperature shelf stability makes it a promising solution for improving mental healthcare practices worldwide.
Impact - Why it Matters
This news matters as NRX Pharmaceuticals' patent application for NRX-100 signifies a groundbreaking development in the treatment of suicidal depression. The potential exclusivity through 2045 and the preservative-free nature of NRX-100 could revolutionize the approach to managing this critical mental health condition. The filing aligns with NRx Pharmaceuticals' mission to provide innovative solutions for central nervous system disorders, offering hope to individuals suffering from suicidal bipolar depression.
Summary
NRx Pharmaceuticals, a clinical-stage biopharma company, has filed a patent application for NRX-100, its preservative-free intravenous ketamine formulation targeting suicidal depression. The patent could provide exclusivity through 2045 if granted. NRX-100 is designed without benzethonium chloride or other preservatives linked to toxicity and has shown room temperature shelf stability—potentially qualifying it for FDA Orange Book listing. This filing supports the company’s NDA submission strategy and complements the FDA Fast Track Designation of companion drug NRX-101.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, NRx Pharmaceuticals Files Patent for NRX-100 IV Ketamine Formulation for Suicidal Depression
